Two popular supplements can ‘interfere’ with vitamin K in the body - risk of haemorrhaging
Taking too much vitamin E and vitamin A in supplement form could have a dangerous effect on the body, an expert has warned. (Source: Daily Express - Health)
Source: Daily Express - Health - October 18, 2022 Category: Consumer Health News Source Type: news

Vitamin A supplements lead to 'complete restoration' of woman's vision in just 5 months
The woman was wrongly suspected of having glaucoma when she was actually suffering from vitamin A deficiency. (Source: Daily Express - Health)
Source: Daily Express - Health - October 14, 2022 Category: Consumer Health News Source Type: news

Former Gov. Patterson to deliver keynote address at Upstate ’s Center for Vision Research 25th anniversary celebration Oct. 21
In addition to Patterson, the event will feature presentations from researchers across the country who will report on progress using genetics to improve glaucoma treatments, optic nerve injury, retinal disease, and other vision afflictions. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - October 13, 2022 Category: Universities & Medical Training Tags: News Research Source Type: news

Former Gov. Paterson to deliver keynote address at Upstate ’s Center for Vision Research 25th anniversary celebration Oct. 21
In addition to Paterson, the event will feature presentations from researchers across the country who will report on progress using genetics to improve glaucoma treatments, optic nerve injury, retinal disease, and other vision afflictions. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - October 13, 2022 Category: Universities & Medical Training Tags: News Research Source Type: news

Immune responses in mice after blast-mediated traumatic brain injury TBI autonomously contributes to retinal ganglion cell dysfunction and death - Harper MM, Gramlich OW, Elwood BW, Boehme NA, Dutca LM, Kuehn MH.
PURPOSE: The purpose of this study was to examine the role of the immune system and its influence on chronic retinal ganglion cell (RGC) dysfunction following blast-mediated traumatic brain injury (bTBI). METHODS: C57BL/6J and B6.129S7-Rag1(tm1Mom)... (Source: SafetyLit)
Source: SafetyLit - October 11, 2022 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Gene Therapy Shows Potential for RPE65-Related Retinal Dystrophy Gene Therapy Shows Potential for RPE65-Related Retinal Dystrophy
The rare genetic retinal disorder results in severe visual impairment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

AI-Enabled Retinal Vasculometry May Help Assess Vascular Health
WEDNESDAY, Oct. 5, 2022 -- Artificial intelligence (AI)-enabled retinal vasculometry (RV) can help predict circulatory mortality, incident stroke, and myocardial infarction (MI), according to a study published online Oct. 4 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2022 Category: Pharmaceuticals Source Type: news

Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
In this study, patients (n=17) were sequentially enrolled at a low, intermediate and high dose without steroid prophylaxis, and all three doses of JNJ-1887 met the primary endpoint of safety over the two-year follow-up period.6 In addition, the supportive efficacy measures, including evaluation of GA lesion growth rates, showed a continual decline in lesion growth over six-month increments.6 These results are the first shared from the Company's common eye disease portfolio and indicate further evaluation of this investigational gene therapy is warranted.6About the Phase 1/2 MGT009 Trial and Botaretigene SparoparvovecThe Ph...
Source: Johnson and Johnson - October 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
IRVINE, Calif. – Sept. 27, 2022 – Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight , TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light ...
Source: Johnson and Johnson - September 28, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

National Eye Institute Awards $5 Million for Cochrane Eyes and Vision US Project
The award supports critical research to help identify treatments to improve the lives of people suffering from debilitating eye diseases. The National Eye Institute (NEI) has awarded a $5 million grant to  Tianjing Li, PhD, associate professor of  ophthalmology at the University of Colorado School of Medicine, in a continuation of the NEI ’s support of theCochrane Eyes and Vision US Satellite (CEV US Satellite) at the Sue Anschutz-Rodgers Eye Center.The award is one of the largest grants the CU Department of Ophthalmology has received from the NEI and ensures the project will remain on the CU Anschutz Medical Campus...
Source: Cochrane News and Events - September 28, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Dr Hilary's key tips to 'boost' your immunity ahead of 'twindemic' expected to hit UK
From vitamin A to D, certain nutrient-packed foods could offer a helping hand for your immunity as flu and Covid cases are set to surge this winter, shared Doctor Hilary Jones on ITV's Lorraine. (Source: Daily Express - Health)
Source: Daily Express - Health - September 28, 2022 Category: Consumer Health News Source Type: news

Dr Ellie urges Britons to take vitamin A and D now summer is over - how to top up vitamins
Autumn is here, the sun is gone, and so that means supplements make a return. This Morning's Doctor Ellie suggests what to take and how much. (Source: Daily Express - Health)
Source: Daily Express - Health - September 26, 2022 Category: Consumer Health News Source Type: news

Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area
BRISBANE, Calif., September 20, 2022 – Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a state-of-the-art Research & Development (R&D) facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will...
Source: Johnson and Johnson - September 20, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

European Commission approves Roche ’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with afliberceptIn addition, patients treated with Vabysmo received up to 33% fewer median number of injections compared to afliberceptReducing the number of eye injections over time could offer a less burdensome treatment schedule for individuals, their caregivers and healthcare systemsVabysmo simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditionsBasel, 19 September...
Source: Roche Investor Update - September 19, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with afliberceptIn addition, patients treated with Vabysmo received up to 33% fewer median number of injections compared to afliberceptReducing the number of eye injections over time could offer a less burdensome treatment schedule for individuals, their caregivers and healthcare systemsVabysmo simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditionsBasel, 19 September...
Source: Roche Media News - September 19, 2022 Category: Pharmaceuticals Source Type: news